>

Don Cornwell - Pfizer Independent Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>PFE</div>
PFE -- USA Stock  

Trending

  Director
Mr. Wyllie Don Cornwell is an Independent Director of Pfizer Inc. He was Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporationrationration from 1988 until his retirement in August 2009, and served as Vice Chairman of the Board until December 2009. Director of American International Group, Inc. and Avon Products, Inc. Director of the Edna McConnell Clark Foundation. Director of the Wallace Foundation from 2002 until 2012 and previously served as a Director of CVS Caremark for over 10 years. Trustee of Big Brothers Big Sisters of New York City. Through Mr. Cornwells 38year career as an entrepreneur driving the growth of a consumerfocused media company, an executive in the investment banking industry and a director of several significant consumer product and healthcare companies, he has valuable business, leadership and management experience and brings important perspectives on the issues facing Pfizer. Mr. Cornwell founded and built Granite, a consumerfocused media company, through acquisitions and operating growth, enabling him to provide insight and guidance on strategic direction and growth
Age: 69  Director Since 1997      
212 733-2323  www.pfizer.com
Cornwell?s strong financial background, including his work at Goldman Sachs prior to cofounding Granite and his service and leadership on the audit, finance and investment committees of other companies, also provides financial expertise to the Board, including an understanding of financial statements, corporate finance, accounting and capital markets.

Management Efficiency

The company has Return on Asset of 0.09 % which means that on every $100 spent on asset it made $0.09 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.0 % .
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Judy LewentGlaxoSmithKline PLC
2011
Juan LucianoEli Lilly And Company
2019
Jose BaselgaBristol Myers Squibb Company
2018
Tim JacksonSmithAstrazeneca PLC
2015
Thomas CechMerck Company
2009
Inge ThulinMerck Company
2018
JeanPhilippe CourtoisAstrazeneca PLC
2008
Wendell WeeksMerck Company
2004
Laurie GlimcherGlaxoSmithKline PLC
2017
Marc DunoyerAstrazeneca PLC
2013
Ron TaylorAllergan Plc
2013
Peter WendellMerck Company
2003
Hans WijersGlaxoSmithKline PLC
2013
Michael GrobsteinBristol Myers Squibb Company
2007
William HarrisonMerck Company
2009
Thomas FreymanAllergan Plc
2018
Gerald StorchBristol Myers Squibb Company
2012
Ann CairnsAstrazeneca PLC
2014
David HooverEli Lilly And Company
2009
Karen VousdenBristol Myers Squibb Company
2018
Michael EskewEli Lilly And Company
2008

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer (PFE) is traded on BATS Exchange in USA. It is located in 235 East 42nd Street, New York, NY 10017, United States and employs 88,300 people. Pfizer is listed under Pharmaceutical Products category by Fama And French industry classification.

Pfizer Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela HwangView
Jennifer Damico, Senior Vice President Principal Accounting Officer, ControllerView
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global SupplyView
Douglas Lankler, Executive Vice President General CounselView
Dawn Rogers, Chief Human Resource Officer, Executive Vice PresidentView
Helen Hobbs, Independent DirectorView
Shantanu Narayen, Lead Independent DirectorView
James Smith, Independent DirectorView
Dennis Ausiello, Independent DirectorView
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and MedicalView
Susan DesmondHellmann, DirectorView
Frances Fergusson, Independent DirectorView
Stephen Sanger, Independent DirectorView
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital OfficerView
Gordon Loh, Senior Vice President Corporate AuditView
Wyllie Cornwell, Independent DirectorView
Suzanne Johnson, Independent DirectorView
Alexander Mackenzie, Executive Vice President Chief Development OfficerView
Geno Germano, Group President of Global Innovative Pharma Bus.View
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial OperationsView
Sally Susman, Chief Corporate Affairs Officer, Executive Vice PresidentView
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global SupplyView
Susan Hockfield, Independent DirectorView
Freda LewisHall, Executive Vice President Chief Medical OfficerView
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice PresidentView
Dan Littman, Independent DirectorView
Ian Read, Chairman, CEO and Chairman of Executive CommitteeView
James Kilts, Independent DirectorView
Don Cornwell, Independent DirectorView
James Quincey, Independent DirectorView
Charles Hill, Executive Vice President - Worldwide Human ResourcesView
Joseph Echevarria, Independent DirectorView
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare BusinessView
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global SupplyView
Angela Hwang, Group President, Pfizer Biopharmaceuticals GroupView
Scott Gottlieb, Independent DirectorView
Ronald Blaylock, Independent DirectorView
Kathrin Jansen, Senior Vice President - Vaccine Research & DevelopmentView
Michael Goettler, Group President - Pfizer UpjohnView

Stock Performance Indicators

Current Sentiment - PFE

Pfizer Investor Sentiment

Predominant part of Macroaxis users are at this time bullish on Pfizer. What is your perspective on investing in Pfizer? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

CRM   
Purchased over 20 shares of
six days ago
Traded for 134.32
C   
Purchased over 70 shares of
six days ago
Traded for 39.23
S   
Purchased over 300 shares of
six days ago
Traded for 8.62
C   
Purchased over 70 shares of
six days ago
Traded for 39.23
DD   
Purchased over 90 shares of
six days ago
Traded for 32.5
Please check Your Equity Center. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page